Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis.

"within the kyn pathway we observed an elevated level of quin (as well as the ratio of quin to its precursor 3haa ( figure 1 ) and a decreased level of kyna ( figure 1c ) and of the ratio between xana and its precursor 3-hydroxykynurenine in patients with ra ( figure 1d ) 10 1136/ard-2023-224014 supp1 supplementary data 10 1136/ard-2023-224014 supp2 supplementary data table 1 espoir population studied ra (espoir cohort) healthy subjects n 574 98 age (years) 48 9?; expression in joint ( online supplemental figure 6b ) 10 1136/ard-2023-224014 supp6 supplementary data 10 1136/ard-2023-224014 supp5 supplementary data figure 5 kynurenine pathway (a) and aadat level (b)."

"Competing interests: HS reports lecture fee, board membership, or consultancy from Amgen, Fresenius, IPSEN, Actial, Astellas, Danone, THAC, Biose, BiomX, Eligo, Immusmol, Adare, Nestle, Ferring, MSD, Bledina, Pfizer, Biocodex, BMS, Bromatech, Gilead, Janssen, Mayoli, Roche, Sanofi, Servier, Takeda, AbbVie; has stocks from Enterome bioscience; and is co-founder of Exeliom Biosciences. JS reports lecture fee, board membership, or consultancy from AbbVie, MSD, Biogen, Pfizer, BMS, Galapagos, Fresenius Kabi, AstraZeneca, UCB, Chugai, Novartis and Janssen. XM report consultancy for AstraZeneca, BMS, Galapagos, GSK, Novartis and Pfizer. D Mulleman received invitation to attend congress: Celltrion healthcare and GSK."

"Funding: HS received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Programme (ERC-2016-StG-71577). This project was partly funded by the Region GRAND EST, the FEDER project "Target (Translational research in ARticular and Gastroinstestinal inflammatory diseases in Grand EsT)" and Fondation Arthritis."